{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:18Z","timestamp":1790352198373,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2023-RW320-01, 2019XK32022"],"award-info":[{"award-number":["2023-RW320-01, 2019XK32022"]}]},{"name":"the CAMS Innovation Fund for Medical Science","award":["2024-I2M-C&T-B-005"],"award-info":[{"award-number":["2024-I2M-C&T-B-005"]}]},{"name":"Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["2022YFC2504600"],"award-info":[{"award-number":["2022YFC2504600"]}]},{"DOI":"10.13039\/501100001809","name":"Nation Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81501414"],"award-info":[{"award-number":["81501414"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03724-3","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:56:21Z","timestamp":1768568181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A BAFF\/APRIL dual inhibitor for the treatment of systemic lupus erythematosus: a long-term, observational, real-world study"],"prefix":"10.1186","volume":"28","author":[{"given":"Yi","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0899-5703","authenticated-orcid":false,"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"3724_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel CH, Sammaritano LR. Systemic lupus erythematosus: a review. JAMA. 2024;331:1480\u201391.","journal-title":"JAMA"},{"key":"3724_CR2","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi A, Igel T, Mok CC, et al. Systemic lupus erythematosus. Lancet. 2024;403:2326\u201338.","journal-title":"Lancet"},{"key":"3724_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82:351\u20136.","journal-title":"Ann Rheum Dis"},{"key":"3724_CR4","doi-asserted-by":"publisher","first-page":"101865","DOI":"10.1016\/j.berh.2023.101865","volume":"37","author":"A Askanase","year":"2023","unstructured":"Askanase A, Khalili L, Tang W, et al. New and future therapies: changes in the therapeutic armamentarium for SLE. Best Pract Res Clin Rheumatol. 2023;37:101865.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3724_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103648","volume":"23","author":"L Arnaud","year":"2024","unstructured":"Arnaud L, Chasset F, Martin T. Immunopathogenesis of systemic lupus erythematosus: an update. Autoimmun Rev. 2024;23:103648.","journal-title":"Autoimmun Rev"},{"key":"3724_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102873","volume":"132","author":"L Arbitman","year":"2022","unstructured":"Arbitman L, Furie R, Vashistha H. B cell-targeted therapies in systemic lupus erythematosus. J Autoimmun. 2022;132:102873.","journal-title":"J Autoimmun"},{"key":"3724_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102861","volume":"132","author":"H Lou","year":"2022","unstructured":"Lou H, Ling GS, Cao X. Autoantibodies in systemic lupus erythematosus: from immunopathology to therapeutic target. J Autoimmun. 2022;132:102861.","journal-title":"J Autoimmun"},{"key":"3724_CR8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/art.42462","volume":"75","author":"LS Evans","year":"2023","unstructured":"Evans LS, Lewis KE, DeMonte D, et al. Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B Cell-Related autoimmune diseases. Arthritis Rheumatol. 2023;75:1187\u2013202.","journal-title":"Arthritis Rheumatol"},{"key":"3724_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169084","volume":"14","author":"J Cai","year":"2023","unstructured":"Cai J, Gao D, Liu D, et al. Telitacicept for autoimmune nephropathy. Front Immunol. 2023;14:1169084.","journal-title":"Front Immunol"},{"key":"3724_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","volume":"25","author":"MV Jonsson","year":"2005","unstructured":"Jonsson MV, Szodoray P, Jellestad S, et al. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sj\u00f6gren\u2019s syndrome. J Clin Immunol. 2005;25:189\u2013201.","journal-title":"J Clin Immunol"},{"key":"3724_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102736","volume":"20","author":"T M\u00f6ckel","year":"2021","unstructured":"M\u00f6ckel T, Basta F, Weinmann-Menke J, et al. B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. 2021;20:102736.","journal-title":"Autoimmun Rev"},{"key":"3724_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","volume":"10","author":"FB Vincent","year":"2014","unstructured":"Vincent FB, Morand EF, Schneider P, et al. The BAFF\/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10:365\u201373.","journal-title":"Nat Rev Rheumatol"},{"key":"3724_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149095","volume":"131","author":"Y Atisha-Fregoso","year":"2021","unstructured":"Atisha-Fregoso Y, Toz B, Diamond B. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Invest. 2021;131:e149095.","journal-title":"J Clin Invest"},{"key":"3724_CR14","volume":"2","author":"JA Singh","year":"2021","unstructured":"Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2:CD010668.","journal-title":"Cochrane Database Syst Rev"},{"key":"3724_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12016-018-8675-2","volume":"54","author":"F Trentin","year":"2018","unstructured":"Trentin F, Gatto M, Zen M, et al. Effectiveness, tolerability, and safety of belimumab in patients with refractory SLE: a review of observational clinical-practice-based studies. Clin Rev Allergy Immunol. 2018;54:331\u201343.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3724_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83:475\u201387.","journal-title":"Ann Rheum Dis"},{"key":"3724_CR17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Telitacicept: first approval. Drugs. 2021;81:1671\u20135.","journal-title":"Drugs"},{"key":"3724_CR18","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","volume":"393","author":"RF van Vollenhoven","year":"2025","unstructured":"van Vollenhoven RF, Wang L, Merrill JT, et al. A phase 3 trial of telitacicept for systemic lupus erythematosus. N Engl J Med. 2025;393:1475\u201385.","journal-title":"N Engl J Med"},{"key":"3724_CR19","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"3724_CR20","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al. 2019 European league against Rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3724_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","volume":"11","author":"KM Luijten","year":"2012","unstructured":"Luijten KM, Tekstra J, Bijlsma JW, et al. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev. 2012;11:326\u20139.","journal-title":"Autoimmun Rev"},{"key":"3724_CR22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"Kidney Disease","year":"2024","unstructured":"Kidney Disease. Improving global outcomes (KDIGO) lupus nephritis work Group. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105:S1\u201369.","journal-title":"Kidney Int"},{"key":"3724_CR23","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8:e000538.","journal-title":"Lupus Sci Med"},{"issue":"11","key":"3724_CR24","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/rheumatology\/kead097","volume":"62","author":"RN Cunha","year":"2023","unstructured":"Cunha RN, Saraiva L, Jesus D, et al. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up. Rheumatology (Oxford). 2023;62(11):3627\u201335.","journal-title":"Rheumatology (Oxford)"},{"key":"3724_CR25","doi-asserted-by":"publisher","first-page":"e001074","DOI":"10.1136\/lupus-2023-001074","volume":"10","author":"HZ Jin","year":"2023","unstructured":"Jin HZ, Li YJ, Wang X, et al. Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study. Lupus Sci Med. 2023;10:e001074.","journal-title":"Lupus Sci Med"},{"key":"3724_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.515","volume":"5","author":"L Ji","year":"2024","unstructured":"Ji L, Geng Y, Zhang X, et al. B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept. MedComm (2020). 2024;5:e515.","journal-title":"MedComm (2020)"},{"key":"3724_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s10067-025-07348-5","volume":"44","author":"F Fang","year":"2025","unstructured":"Fang F, Duan H, Ding S. Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study. Clin Rheumatol. 2025;44:1113\u201322.","journal-title":"Clin Rheumatol"},{"key":"3724_CR28","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10157-024-02501-x","volume":"28","author":"X Huang","year":"2024","unstructured":"Huang X, Lin F, Chen H. Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study. Clin Exp Nephrol. 2024;28:902\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"3724_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10067-024-07266-y","volume":"44","author":"HZ Jin","year":"2025","unstructured":"Jin HZ, Cai ML, Wang X, et al. Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study. Clin Rheumatol. 2025;44:247\u201356.","journal-title":"Clin Rheumatol"},{"key":"3724_CR30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/09612033251332052","volume":"34","author":"J Zhang","year":"2025","unstructured":"Zhang J, Sun Y, Zhang N, et al. Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: a retrospective real-world study. Lupus. 2025;34:597\u2013607.","journal-title":"Lupus"},{"key":"3724_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1645826","volume":"16","author":"X Liu","year":"2025","unstructured":"Liu X, Li N, Wu P, et al. Research paper efficacy and safety of telitacicept combined with standard therapy for lupus nephritis: a single-center real-world study. Front Immunol. 2025;16:1645826.","journal-title":"Front Immunol"},{"key":"3724_CR32","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s10067-024-06992-7","volume":"43","author":"J Cheng","year":"2024","unstructured":"Cheng J, Peng Y, Wu Q, et al. Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement. Clin Rheumatol. 2024;43:2229\u201336.","journal-title":"Clin Rheumatol"},{"key":"3724_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10238-025-01640-z","volume":"25","author":"T Feng","year":"2025","unstructured":"Feng T, Zhang M, Wang J, et al. Evaluation of the efficacy and safety of belimumab and telitacicept in patients with systemic lupus erythematosus: results from a retrospective, observational study. Clin Exp Med. 2025;25:105.","journal-title":"Clin Exp Med"},{"key":"3724_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114596","volume":"154","author":"L Chen","year":"2025","unstructured":"Chen L, Teng Y, Ma Q, et al. Efficacy and safety of telitacicept in patients with class III-V lupus nephritis: a real-world retrospective cohort study. Int Immunopharmacol. 2025;154:114596.","journal-title":"Int Immunopharmacol"},{"key":"3724_CR35","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1093\/ndt\/gfaf049","volume":"40","author":"J Jin","year":"2025","unstructured":"Jin J, Tan M, Tan Y, et al. Real world data on dual BLyS\/APRIL inhibition with telitacicept for lupus nephritis. Nephrol Dial Transplant. 2025;40:1775\u201385.","journal-title":"Nephrol Dial Transplant"},{"key":"3724_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","volume":"21","author":"M Stockfelt","year":"2025","unstructured":"Stockfelt M, Teng YKO, Vital EM. Opportunities and limitations of B cell depletion approaches in SLE. Nat Rev Rheumatol. 2025;21:111\u201326.","journal-title":"Nat Rev Rheumatol"},{"key":"3724_CR37","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74:2006\u201315.","journal-title":"Ann Rheum Dis"},{"key":"3724_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018;70:266\u201376.","journal-title":"Arthritis Rheumatol"},{"key":"3724_CR39","doi-asserted-by":"publisher","first-page":"1472292","DOI":"10.3389\/fimmu.2024.1472292","volume":"15","author":"S Gao","year":"2025","unstructured":"Gao S, Yang C, Huang B, et al. Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in china: a systematic review and meta-analysis. Front Immunol. 2025;15:1472292.","journal-title":"Front Immunol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03724-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03724-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03724-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:06:25Z","timestamp":1770771985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-025-03724-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3724"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03724-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Peking Union Medical College Hospital [K24C2297]. All patients in this study provided written informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}